Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has announced its participation in two upcoming investor conferences in September 2025.
The company will participate in Citi's 2025 Biopharma Back to School Conference with a fireside chat on September 2 at 3:15 p.m. ET, and the Cantor Global Healthcare Conference 2025 with a fireside chat on September 5 at 9:10 a.m. ET. Both presentations will be available via webcast on the company's website for 90 days.
Positive
- None.
Negative
- None.
NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in the following upcoming investor conferences.
Citi’s 2025 Biopharma Back to School Conference
Date/Time: Fireside chat on Tuesday, September 2, 2025 at 3:15 p.m. ET
Cantor Global Healthcare Conference 2025
Date/Time: Fireside chat on Friday, September 5, 2025 at 9:10 a.m. ET
The live webcasts may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When is Acumen Pharmaceuticals (NASDAQ: ABOS) presenting at Citi's Biopharma Conference 2025?
What time is Acumen's presentation at the Cantor Global Healthcare Conference 2025?
Where can investors access Acumen Pharmaceuticals' (ABOS) conference presentations?
What is Acumen Pharmaceuticals' (ABOS) main focus in drug development?
